Details
Test your knowledge of ATTR cardiomyopathy with #ESCTVToday
https://ow.ly/iJcX50Zq38T
Can you identify the statement that doesn't align with current recommendations?
SGLT2 inhibitors should become a pillar of the treatment of patients with ATTR cardiomyopathy.
Pharmacological management of ATTR cardiomyopathy should be typical of any other heart failure.
Loop diuretics are essential to treat symptoms.
Disease-modifying therapy for TTR cardiac amyloidosis includes gene silencers and TTR stabilisers.
The role of implantable cardioverter defibrillators in ATTR cardiomyopathy remains unclear.